Live bacterial therapeutics (LBTs) that engraft in the gut and provide persistent beneficial functions to the host have emerged as a promising strategy against a wide range of diseases.
Scientists from the University Grenoble Alpes in France and colleagues have recently identified a promising drug candidate with broad-spectrum activity against apicomplexans using a drug repurposing strategy.
Tarsier Pharma is developing the small molecule TRS as an anti-inflammatory treatment for retinal diseases, with the eye drop formulation TRS-01 in phase III development for noninfectious anterior uveitis and uveitic glaucoma.
Secretion of gastric acid is tightly controlled by the neuroendocrine system of the stomach, formed by an interconnected network of nerves and different hormone-producing cell types, particularly G cells that release the hormone gastrin.
CGeneTech announced that the ALK inhibitor CGT-9475, which was independently developed by Shengshi Tyco, has been approved by the FDA to enter clinical trials aiming to evaluate the candidate's ability to overcome the issues of drug resistance and brain metastasis in the treatment of lung cancer.
Homology Medicines announced the details of its optimized, in vivo, one-time gene therapy product candidate, HMI-204, being developed for the treatment of metachromatic leukodystrophy (MLD).
Cullgen announced that the Chinese National Medical Products Administration (NMPA) has allowed the IND application for CG-001419, a first-in-class, selective, potent oral targeted protein tyrosine receptor kinase (TRK) degrader for the treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive cancers, which have been identified in numerous solid tumors including non-small cell lung, breast and pancreatic cancers.
Athira Pharma has presented data on the development and evaluation of novel orally bioavailable, blood-brain-barrier-penetrant small-molecule hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (MET) positive modulators for the potential treatment of cognitive impairment.
Ceapro announced that it has entered into an additional research project expanding on the ongoing collaboration with McMaster University to develop an inhalable immuno-therapeutic/-prophylactic for COVID-19-induced lung fibrosis.
RSS